Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
8 min read
Hypogonadotropic hypogonadism Indication Strategy Report 2026: GnRH receptor, Trials and Deals
24 July 2026
2026 Hypogonadotropic hypogonadism strategy: epidemiology, GnRH receptor biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Oligospermia Indication Strategy Report 2026: FSH receptor, Trials and Deals
24 July 2026
2026 Oligospermia strategy: epidemiology, FSH receptor biology, clinical competition, recent deals, unmet need and market attractiveness. Evidence synthesized…
Latest Hotspot
8 min read
Nonobstructive azoospermia Indication Strategy Report 2026: Retinoic acid receptor, Trials and Deals
24 July 2026
2026 Nonobstructive azoospermia strategy: epidemiology, Retinoic acid receptor biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Male infertility Indication Strategy Report 2026: FSH receptor, Trials and Deals
24 July 2026
2026 Male infertility strategy: epidemiology, FSH receptor biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Female infertility Indication Strategy Report 2026: FSH receptor, Trials and Deals
24 July 2026
2026 Female infertility strategy: epidemiology, FSH receptor biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Asherman syndrome Indication Strategy Report 2026: TGF-beta, Trials and Deals
24 July 2026
2026 Asherman syndrome strategy: epidemiology, TGF-beta biology, clinical competition, recent deals, unmet need and market attractiveness. Evidence synthesized…
Latest Hotspot
8 min read
Recurrent pregnancy loss Indication Strategy Report 2026: Complement C5, Trials and Deals
24 July 2026
2026 Recurrent pregnancy loss strategy: epidemiology, Complement C5 biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Primary ovarian insufficiency Indication Strategy Report 2026: FSH receptor, Trials and Deals
24 July 2026
2026 Primary ovarian insufficiency strategy: epidemiology, FSH receptor biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Microphthalmia Indication Strategy Report 2026: SOX2, Trials and Deals
24 July 2026
2026 Microphthalmia strategy: epidemiology, SOX2 biology, clinical competition, recent deals, unmet need and market attractiveness. Evidence synthesized with…
Latest Hotspot
8 min read
Axenfeld-Rieger syndrome Indication Strategy Report 2026: FOXC1, Trials and Deals
24 July 2026
2026 Axenfeld-Rieger syndrome strategy: epidemiology, FOXC1 biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Aniridia Indication Strategy Report 2026: PAX6, Trials and Deals
24 July 2026
2026 Aniridia strategy: epidemiology, PAX6 biology, clinical competition, recent deals, unmet need and market attractiveness. Evidence synthesized with PatSnap…
Latest Hotspot
8 min read
Congenital glaucoma Indication Strategy Report 2026: CYP1B1, Trials and Deals
24 July 2026
2026 Congenital glaucoma strategy: epidemiology, CYP1B1 biology, clinical competition, recent deals, unmet need and market attractiveness. Evidence synthesized…